Bernstein raises Centene stock price target to $90 on Medicaid outlook
Bernstein raised Centene Corp.'s (CNC) price target to $90 from $79, citing strong Q3 results and improved Medicaid prospects. The stock is up 102% in a year. Centene beat EPS estimates and raised full-year guidance, with revenue expected between $196.5B and $200.5B. Analysts highlight undervaluation and growth potential.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the broker’s raised price target and estimate revisions, which can influence positioning and near-term sentiment around managed care and Medicaid-linked earnings durability.
Market read
A bullish sell-side update tied to Medicaid recovery and MLR expectations, but it is not a new Centene corporate disclosure.
What to watch
The article cites a Q3 beat and guidance raises, but it does not quantify Medicaid policy/regulatory risks that could reverse recovery assumptions.
Background
The piece reports Bernstein’s updated valuation and forecast assumptions for Centene, referencing Centene’s Q3 results and Medicaid recovery expectations.
Ticker impact
Bernstein raised Centene’s price target to $90 and lifted EPS and revenue estimates, citing improved Medicaid recovery prospects and Q3 results.
Likely near-term support for the stock as traders price in the raised target and improved Medicaid recovery narrative.
The article is an analyst target/estimate change tied to specific guidance revisions (EPS, revenue, MLR) and a Q3 beat, which typically moves sentiment even if it is not a fresh company disclosure.
Market effects
Reinforces positive sentiment for managed care names tied to Medicaid recovery and medical loss ratio normalization.
Limited, primarily US managed-care sentiment.
Low, largely domestic healthcare reimbursement dynamics.
Counterpoint
Analyst target hikes can lag underlying fundamentals; the key risk is whether Medicaid recovery and MLR improvements persist beyond the forecast window.
Key entities
- companyCentene Corp.
US managed care provider; subject of Bernstein’s raised price target and forecast revisions in the article.
- analyst_firmBernstein SocGen Group
Brokerage raising Centene’s price target to $90 and adjusting EPS, revenue, and MLR expectations.



